Despite being a plasma cell marker, BCMA is also co-expressed on normal B-lymphocytes, therefore, BCMA CAR T-cell therapy could also introduce on-target/off-tumor effects, where the common manifestations include B-cell aplasia, neutropenia, and immunosuppression that leads to increased infection risks. Here, TNFRSF17 is linked to Decreased total neutrophil count.